title: SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa intervencionista).
abstract: In the United States alone, there are currently approximately 14.5 million cancer survivors, and this number is expected to increase to 20 million by 2020. Cancer therapies can cause significant injury to the vasculature, resulting in angina, acute coronary syndromes (ACS), stroke, critical limb ischemia, arrhythmias, and heart failure, independently from the direct myocardial or pericardial damage from the malignancy itself. Consequently, the need for invasive evaluation and management in the cardiac catheterization laboratory (CCL) for such patients has been increasing. In recognition of the need for a document on special considerations for cancer patients in the CCL, the Society for Cardiovascular Angiography and Interventions (SCAI) commissioned a consensus group to provide recommendations based on the published medical literature and on the expertise of operators with accumulated experience in the cardiac catheterization of cancer patients.
authors.affiliation: MD Anderson Cancer Center, University of Texas, Houston, Texas.
authors.forename: Cezar A
authors.initials: CA
authors.lastname: Iliescu
authors.affiliation: Detroit Medical Center, Cardiovascular Institute, Detroit, Michigan.
authors.forename: Cindy L
authors.initials: CL
authors.lastname: Grines
authors.affiliation: Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
authors.forename: Joerg
authors.initials: J
authors.lastname: Herrmann
authors.affiliation: Division of Cardiology, University of California at Los Angeles, Los Angeles, California.
authors.forename: Eric H
authors.initials: EH
authors.lastname: Yang
authors.affiliation: School of Medicine, Arkansas Heart Hospital, Little Rock, Arkansas.|Department of Cardiology, Koc University, Istanbul, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Cilingiroglu
authors.affiliation: Department of Cardiology, University of Texas Health Science Center, Houston, Texas.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Charitakis
authors.affiliation: Department of Cardiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
authors.forename: Abdul
authors.initials: A
authors.lastname: Hakeem
authors.affiliation: Athens Medical School, Hippokration General Hospital, Athens, Greece.
authors.forename: Konstantinos P
authors.initials: KP
authors.lastname: Toutouzas
authors.affiliation: Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama.
authors.forename: Massoud A
authors.initials: MA
authors.lastname: Leesar
authors.affiliation: Department of Cardiology, Citizens Memorial Hospital, Bolivar, Missouri.|Department of Medicine, University of Missouri, Columbia, Missouri.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Marmagkiolis
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D006328:Cardiac Catheterization / Q000009:adverse effects / Q000592:standards*; D002309:Cardiology / Q000592:standards*; D066126:Cardiotoxicity; D032921:Consensus; D017023:Coronary Angiography / Q000009:adverse effects / Q000592:standards*; D006331:Heart Diseases / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy*; D006801:Humans; D008495:Medical Oncology / Q000592:standards*; D009369:Neoplasms / Q000150:complications / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000592:standards*; D011237:Predictive Value of Tests; D011832:Radiation Injuries / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy*; D011878:Radiotherapy / Q000009:adverse effects; D012307:Risk Factors; D017741:Survivors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
keywords: PCI; cancer; cardio-oncology; malignancy; stent thrombosis